Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Fusce ullamcorper dapibus
Original price was: $55.00.$41.00Current price is: $41.00.Add to cartVestibulum quis augue sem. Curabitur non vehicula elit, et cursus tortor. Quisque placerat velit nec nulla sodales, porttitor mattis tortor porta. Praesent gravida leo nibh, vel semper nulla lobortis vel. Donec nisl velit, iaculis ac dolor eget, blandit elementum urna. Mauris pellentesque posuere pellentesque. Nunc fermentum purus a consequat fringilla. Donec finibus suscipit erat in pharetra
-
Quick View
Nunc tempus facilisis
$87.00Add to cartFusce ullamcorper dapibus eleifend. Nullam ornare pulvinar lacinia. Nunc tempus facilisis ullamcorper. Nam sit amet suscipit risus, ut ultricies felis. Vivamus a finibus nisi. Sed quam sem, accumsan eget tristique sit amet, suscipit sit amet augue. Duis dolor dui, sagittis at faucibus ac, varius et sapien.
-
Quick View
Fusce nec diam et dolor
$45.00Add to cartFusce nec diam et dolor ornare rhoncus nec ut mauris. In eleifend mi in felis dictum fermentum. Morbi vel arcu sit amet dolor venenatis bibendum in eu dui. Nulla velit dolor, imperdiet consectetur luctus ut, faucibus eget est.
-
Quick View
Suspendisse vehicula at dui
$56.00Add to cartMorbi mattis ipsum sem, in gravida dolor venenatis vestibulum. Aenean laoreet, nisi in bibendum dictum, purus libero accumsan enim, id vehicula enim metus vitae ipsum. Maecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat. Quisque ultricies ornare lacus, eu sagittis urna euismod ac. Nulla rhoncus ultrices ligula, id maximus ligula ultricies non.
Reviews
There are no reviews yet.